# The TWEAK–HOIP–HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation

**Authors:** Zongnan Ding, Enzhuo Liu, Xinyue Li, Yujie Zhang, Lei Li, Chenghua Weng, Zhiqin Liu, Zhichun Liu

PMC · DOI: 10.1155/mi/4149395 · Mediators of Inflammation · 2026-03-02

## TL;DR

This study identifies a new signaling pathway involving TWEAK, HOIP, and HuR that causes abnormal cell growth in lupus nephritis, offering potential new treatment targets.

## Contribution

The study reveals a novel TWEAK–HOIP–AMPK–HuR signaling axis linking metabolic changes to cell proliferation in lupus nephritis.

## Key findings

- TWEAK signaling causes AMPK inactivation via HOIP-mediated ubiquitination.
- AMPK suppression leads to cytoplasmic HuR accumulation and Cyclin D1 mRNA stabilization.
- HOIP depletion reverses AMPK inactivation and reduces mesangial cell proliferation.

## Abstract

Cellular proliferation is intrinsically coupled to metabolic reprogramming, a conserved biological association that modulates the progression of diverse proliferative pathologies. In the present study, we unveil a novel mechanistic link between tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) signaling and Human antigen R (HuR)‐driven metabolic alterations in lupus nephritis (LN), a progressive renal disorder characterized by mesangial cells (MCs) hyperproliferation and glomerular dysfunction. We demonstrate that TWEAK stimulation elicits linear ubiquitination of AMP‐activated protein kinase (AMPK)—a master regulator of cellular energy metabolism—mediated by the E3 ubiquitin ligase HOIL‐1‐interacting protein (HOIP). This posttranslational modification directly results in the functional inactivation of AMPK. Notably, suppressed AMPK activity drives the nuclear export of HuR, a ubiquitously expressed RNA‐binding protein, leading to its subsequent accumulation in the cytoplasmic compartment. In the cytosol, HuR selectively binds to and stabilizes the mRNAs of key cell cycle regulators, with Cyclin D1 being a primary target. This stabilization of Cyclin D1 mRNA ultimately promotes aberrant MCs proliferation, a pathological hallmark of LN. To validate the functional relevance of the pathogenesis, we performed HOIP knockdown experiments in MCs. Consistent with our mechanistic model, HOIP depletion significantly restored AMPK phosphorylation (a well‐established surrogate marker of AMPK activation), suppressed HuR cytoplasmic shuttling, reduced Cyclin D1 expression at both the transcriptional and translational levels, and ultimately inhibited aberrant MCs proliferation in vitro. Collectively, our results establish the TWEAK–HOIP–AMPK–HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.

## Linked entities

- **Genes:** TNFSF12 (TNF superfamily member 12) [NCBI Gene 8742], RNF31 (ring finger protein 31) [NCBI Gene 55072], PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994], ccnd1.S (cyclin D1 S homeolog) [NCBI Gene 379161]
- **Proteins:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1), RNF31 (ring finger protein 31), ELAVL1 (ELAV like RNA binding protein 1)
- **Diseases:** lupus nephritis (MONDO:0005556)

## Full-text entities

- **Genes:** PRKCA (protein kinase C alpha) [NCBI Gene 5578] {aka AAG6, PKC-alpha, PKCA, PKCI+/-, PKCalpha}, Ccnd1 (cyclin D1) [NCBI Gene 12443] {aka CycD1, Cyl-1, PRAD1, bcl-1, cD1}, TNFSF12 (TNF superfamily member 12) [NCBI Gene 8742] {aka APO3L, DR3LG, TNF12, TNLG4A, TWEAK}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TNFRSF12A (TNF receptor superfamily member 12A) [NCBI Gene 51330] {aka CD266, FN14, TWEAKR}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, TRPM7 (transient receptor potential cation channel subfamily M member 7) [NCBI Gene 54822] {aka ALSPDC, CHAK, CHAK1, LTRPC7, LTrpC-7, TRP-PLIK}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Tnfsf12 (tumor necrosis factor (ligand) superfamily, member 12) [NCBI Gene 21944] {aka Apo3l, Dr3l, Dr3lg, Tweak}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, Elavl1 (ELAV like RNA binding protein 1) [NCBI Gene 15568] {aka 2410055N02Rik, HUR, Hua}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, RNF31 (ring finger protein 31) [NCBI Gene 55072] {aka HOIP, IMD115, Paul, ZIBRA}
- **Diseases:** LN (MESH:D008181), cancer (MESH:D009369), end-stage renal disease (MESH:D007676), Renal involvement (MESH:C565423), HMCs (MESH:D015459), metastasis (MESH:D009362), fibrosis (MESH:D005355), Inflammatory (MESH:D007249), embryonic lethality (MESH:D020964), immunodeficiency (MESH:D007153), metabolic dysfunction (MESH:D008659), autoinflammation (MESH:D056660), SLE (MESH:D008180), glomerular dysfunction (MESH:D007674), autoimmune diseases (MESH:D001327)
- **Chemicals:** FITC (MESH:D016650), streptomycin (MESH:D013307), Triton-X 100 (MESH:D017830), Paraffin (MESH:D010232), DMEM (-), CCK- (MESH:D002766), puromycin (MESH:D011691), penicillin (MESH:D010406), SDS (MESH:D012967), PVDF (MESH:C024865), PBS (MESH:D007854), DAPI (MESH:C007293), glucose (MESH:D005947), CO2 (MESH:D002245), CCK-8 (MESH:D012844), Agarose (MESH:D012685), lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HMCs — Homo sapiens (Human), Conditionally immortalized cell line (CVCL_W168), MRL/lpr — Mus musculus (Mouse), Stromal cell line (CVCL_B6HA)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951119/full.md

## Figures

19 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951119/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951119/full.md

---
Source: https://tomesphere.com/paper/PMC12951119